Driven by rapid innovations and the integration of modern technologies, the biotech sector is experiencing robust growth.

Vertex Pharmaceuticals (VRTX) ended the recent trading session ... On the other hand, the Dow registered a loss of 0.06%, and the technology-centric Nasdaq increased by 1.24%.

MaxCyte Inc. (NASDAQ: MXCT) is a global developer of next-generation cell therapies. They provide crucial technology for cell ...

Detailed price information for Vertex Pharmaceutic (VRTX-Q) from The Globe and Mail including charting and trades.

In the latest market close, Vertex Pharmaceuticals (VRTX) reached $409.56 ... Meanwhile, the Dow experienced a drop of 1.63%, and the technology-dominated Nasdaq saw a decrease of 1.63%.

Benchmark upgraded Meta Platforms (META) to Buy from Hold with a $820 price target, citing a "strong" 2025 core business ...

The S&P 500 declined by 0.5% on Friday, Jan. 31, as investors digested the White House’s proposed tariffs on Canada, China, and Mexico.

JOURNAVX is the first and only approved non-opioid oral pain signal inhibitor and the first new class of pain medicine approved in more than 20 years -- ...

Below is Validea's guru fundamental report for VERTEX PHARMACEUTICALS INC (VRTX). Of the 22 guru strategies we follow, VRTX rates highest using our P/B Growth Investor model based on the published ...